Best Practices in Prostacyclin Therapy for Pulmonary Arterial Hypertension in the Hospitalized Patient

Primary Audience:

Hospitalists, Internal Medicine

Supported by an educational grant from:

Actelion Pharmaceuticals

Activity Information

Credits: 0.5 AMA PRA Category 1 Credit(s)™
Launch Date: December 13, 2018
Expiration Date: December 13, 2019

COURSE FACULTY

Ronald J. Oudiz, MD
Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension LA BioMed Research Institute at Harbor-UCLA Medical Center


Timothy M. Fernandes, MD, MPH
Associate Clinical Professor of Medicine
University of California, San Diego
Division of Pulmonary and Critical Care Medicine
Pulmonary Vascular Program
San Diego, CA

LEARNING OBJECTIVES

  1. Assess the clinical trial data, safety, and efficacy of prostacyclin therapies for the management of pulmonary arterial hypertension (PAH).     
  2. Review the role of the hospitalist in the selection, administration, monitoring, and evaluation of side effects of therapies for pulmonary arterial hypertension (PAH).
  3. Identify strategies for collaborative care with specialty centers when managing hospitalized patients with pulmonary arterial hypertension (PAH).

COURSE INFORMATION

CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare
 
 

Physicians

AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
 
Method of Participation Statements of credit will be awarded based on the participant reviewing the entire presentation, scoring a 70% on the post test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Faculty Disclosures

Dr. Fernandez has disclosed the following relevant financial relationships:
Consultant - Actelion
Speakers Bureau - Bayer

Dr. Oudiz has disclosed the following relevant financial relationships:
Consultant - Actelion, Arena, Bayer, Gilead, United Therapeutics
Contract Research - AADi, Actelion, Arena, Bayer, Gilead, Liquidia, Reata, United Therapeutics
Speakers Bureau - Actelion, Bayer, Gilead, United Therapeutics
Accredited Provider Disclosure

STAFF/REVIEWERS
Margaret V. Clark, MSc, RN, RRT - NPS, CMPP, Medical Writer/Interviewer, discloses no financial relationships with pharmaceutical or medical product manufacturers.
Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner, discloses no financial relationships with pharmaceutical or medical product manufacturers.
Patricia Brignoni, AKH Director of Operations: has disclosed no relevant financial relationships.

Steve Eckert, AKH President & CEO, Planner: has disclosed no relevant financial relationships.
 
AKH Inc, planners and reviewers have disclosed no financial relationships with pharmaceutical or medical product manufacturers.

Commercial Support

This activity is supported by an educational grant from Actelion Pharmaceuticals.

Fee

There is no fee to participate in this activity

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
 
Copyright © 2018 No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publishe

COURSE VIEWING REQUIREMENTS

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above        

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.